{"prompt": "['OSTPDL1', 'Page 41 of 60', 'The samples will be processed at The Clinical Support Laboratory at the', 'Frederick National Laboratory for Cancer Research (see Appendix III):', 'Theresa Burks', 'Leido-Frederick', '1050 Boyles Street', 'Bldg 469, Room 121', 'Frederick MD 21702', 'Phone 301-846-5125 or 301-846-1707', 'On days samples are drawn, Jen Bangh at the Clinical Support Laboratory', 'should be notified (phone: (301) 846-5893; fax (301) 846-6536). She', 'will arrange same-day courier delivery of the specimens.', 'The research samples will contain labels on the blood tubes that have the', \"patient's initials, date of birth, the assigned protocol, and the date the\", 'samples were drawn. The transmittal forms accompanying the samples', 'also contain the same information.', \"Once a patient's treatment schedule has been determined, it should be\", 'faxed to Caroline Jochems at the Laboratory of Tumor Immunology and', 'Biology / NIH (Fax: (301) 496-2756; phone: (301) 402-6274) for', 'planning purposes.', 'Parameters of immune activation', 'Immunologic testing will include:', 'Peripheral blood mononuclear cells (PBMC)', 'Phenotypic and functional analysis of 123 immune cell', 'subsets by flow cytometry (CD4, CD8, and regulatory T-', 'lymphocytes, B-lymphocytes, NK cells, NKT cells, dendritic', 'cells, myeloid derived suppressor cells and ratios of effector', 'to suppressor cells).', 'Serum', 'Analysis of cytokines (ifn-y, L-10, IL-12, IL-2, IL-4, TGF-B,', 'etc.), chemokines, soluble CD27, soluble CD40L, antibodies,', 'tumor-associated antigens and/or other markers', 'St. Jude', 'IRB NUMBER: Pro00006856', 'Revision 1.1, dated: 01-19-2018', 'IRB approved: 01-26-3018 APPROVAL DATE: 06/26/2019', 'Protocol document dated: 01-19-2018']['OSTPDL1', 'Page 42 of 60', 'Flow-cytometry analysis of PBMC immune cell subsets: 27 markers,', '123 subsets', '1. CD4: Helper T lymphocytes (33 subsets)', '2. CD8: Cytotoxic T lymphocytes (30 subsets)', 'Maturation status of T lymphocytes (in CD4 and CD8):', '-', 'Na\u00efVe: CD45RA+ CCR74', '-', 'Central Memory: CD45RA CCR7+', '-', 'Effector Memory: CD45RA CCR7', '-', 'Terminal (EMRA): CD45RA+ CCR7', 'T lymphocyte markers (in total and memory CD4 and', 'CD8):', '-', 'CTLA-4: inhibition', '-', 'PD-1: activation/inhibition', '-', 'PD-L1: activation/cross-inhibition', '- TIM-3: inhibition', '-', '41BB: co-stiactivation', '-', 'ICOS: activation (only on CD4)', '3. Tregs: Regulatory T lymphocytes (CD4+ CD25 FoxP3+ CD127`) (7', 'subsets)', 'CD45RA: Tregs highly expandable in vitro', 'CTLA-4: Treg suppression', 'CD49d: \"contaminating\" effector lymphocytes (non-Tregs)', 'ICOS: Treg suppression', 'PD-1: activation/inhibition', 'PD-L1: cross-inhibition', '4. B lymphocytes: CD19+ (3 subsets)', 'PD-1: activation/inhibition', 'PD-L1: cross-inhibition', '5. NK: Natural killer cells (CD56+ CD3 (20 subsets)', 'CD16+ CD56dim : Mature NK, lytic', 'CD16+ CD56br Functional intermediate, lytic, cytokine', 'production', 'CD16 CD56br Immature, cytokine production, abundant in', 'placenta', 'CD16 CD56dim non-lytic, non-cytokine production', 'TIM-3: activation', 'PD-1: activation/inhibition', 'PD-L1: cross-inhibition', '6. NK-T: CD56+ CD34 (4 subsets)', 'TIM-3: activation', 'PD-1 activation/inhibition', 'PD-L1: cross-inhibition', '7. cDCs (Conventional DCs): CD3 CD56HLA-DR*CD1c+CD303 (5', 'subsets)', '8. pDCs (plasmacytoid DCs ): CD3 CD56 HLA-DR+CD1CCD303+ (5', 'subsets)', 'Markers of DC activation', '-', 'CD83: activation', '- TIM-3: inhibition', '-', 'PD-L1: cross-inhibition', '-', 'PD1: activation/inhibition', '9. MDSCs: Mveloid-derived suppressor cells (CD11b+ HLA-D', 'StowJude', 'IRB NUMBER: Pro00006856', 'Revision 1.1, dated: 01-19-2018', 'IRB approved: 01-26-201 RPPROVAL DATE: 06/26/2019', 'Protocol document dated: 01-19-2018']\n\n###\n\n", "completion": "END"}